The European BRCA patent oppositions and appeals: Coloring inside the lines

Nature Biotechnology

Volumn 31, Issue 8, 2013, Pages 704-710

  Matthijs, Gert ^a   Huys, Isabelle ^a   Van Overwalle, Geertrui ^a,b   Stoppa Lyonnet, Dominique ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b TILBURG UNIVERSITY   (Netherlands)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BILLING AND CLAIMS; DIAGNOSTIC PROCEDURE; EUROPE; FRAMESHIFT MUTATION; HUMAN; LEGAL ASPECT; MOLECULAR GENETICS; NONHUMAN; ORGANIZATION; PATENT; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UNITED STATES;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; EUROPE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PATIENTS;

EID: 84883747114     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2644     Document Type: Article

References (46)

1. Davies, K. & White, M. Breakthrough: The Race to Find the Breast Cancer Gene (J. Wiley, Hoboken, NJ, USA, 1996).
2. Dalpé, R. et al. Sci. Technol. Human Values 28, 187-216 (2003).
3. Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al. 702 F.Supp. 2d 181, 192-211 (SDNY, 2010).
4. Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al. US 12-398 (2013).
5. Matthijs, G. Fam. Cancer 5, 95-102 (2006).
6. In 2004, Myriad Genetics transferred its rights on the different patents to the University of Utah Research Foundation. Strictly speaking, one can thus no longer call them the "Myriad patents." Still, it is generally known that Myriad is the exclusive licensee, so for the purpose of this survey, the change in patent ownership is of no relevance.
7. Matloff, E.T. & Brierley, K.L. Lancet 376, 314-315 (2010).
8. Cook-Deegan, R. et al. Genet. Med. 12, S15-S38 (2010).
9. Myriad. Integrated BRACAnalysis to include BART. (2012).
10. Miki, Y. et al. Science 266, 66-71 (1994).
11. Futreal, P.A. et al. Science 266, 120-122 (1994).
12. Wooster, R. et al. Nature 378, 789-792 (1995).
13. Huys, I. et al. Eur. J. Hum. Genet. 19, 1104-1107 (2011).
14. Huys, I. et al. Nat. Rev. Genet. 13, 441-448 (2012).
15. T1213/05 (Breast and ovarian cancer/UNIVERSITY OF UTAH) of 27.9.2007.
16. G2/98, OJ EPO 2001, 413.
17. T0666/05 (Mutation/UNIVERSITY OF UTAH) of 13.11.2008.
18. T923/92, OJ EPO 1996.
19. T0351/01 (Tissue Factor Protein/GENENTECH) of 2.7.2003.
20. T70/05 (Apoptosis receptors/GENENTECH) of 7.2.2006.
21. T0030/02 (Xylanase/NOVOZYMES) of 9.10.2006.
22. T0080/05 (Method of diagnosis/UNIVERSITY OF UTAH) of 19.11.2008.
23. Caux-Moncoutier, V. et al. Hum. Mutat. 32, 325-334 (2011).
24. T0156/08 (BRCA2/UNIVERSITY OF UTAH) of 14.1.2011.
25. T0902/07 (BRCA2/CANCER RESEARCH TECHNOLOGY) of 7.9.2010.
26. Cho, M. Trends Biotechnol. 28, 548-551 (2010).
27. Rimmer, M. Intellectual Property and Biotechnology: Biological Inventions (Edward Elgar, Cheltenham, UK, 2008).
28. Actavis Group & Alfred E. Tiefenbacher GmbH v. Merck Sharp & Dohme Corp. Tribunal de Grande Instance de Paris, third chamber, 28 September 2010, N° RG: 07/16296.
29. Hopkins, M.M. & Hogarth, S. Nat. Biotechnol. 30, 498-500 (2012).
30. Graff, G.D. et al. Nat. Biotechnol. 31, 404-410 (2013).
31. Cook-Deegan, R., Conley, J.M., Evans, J.P. & Vorhaus, D. Eur. J. Hum. Genet. 21, 585-588 (2012).
32. Lenoir, G.M. et al. Cancer Res. 50, 4448-4449 (1990).
33. Hall, J.M. et al. Science 250, 1684-1689 (1990).
34. Easton, D.F. et al. Am. J. Hum. Genet. 52, 678-701 (1993).
35. Narod, S.A. et al. Lancet 338, 82-83 (1991).
36. Albertsen, H. et al. Am. J. Hum. Genet. 54, 516-525 (1994).
37. Friedman, L.S. et al. Nat. Genet. 8, 399-404 (1994).
38. Wooster, R. et al. Science 265, 2088-2090 (1994).
39. Tavtigian, S.V. et al. Nat. Genet. 12, 333-337 (1996).
40. Lalloo, F. & Evans, D.G. Clin. Genet. 82, 105-114 (2012).
41. Ripperger, T. et al. Eur. J. Hum. Genet. 17, 722-731 (2009).
42. Williams-Jones, B. Health Law J. 10, 123-146 (2002).
43. Gold, E.R. & Carbone, J. Myriad: In the Eye of the Policy Storm. (The Innovation Partnership and the McGill Centre for Intellectual Property Policy, 2008).
44. Munktell, P. Compulsory Patent Licensing. (Master's thesis, Univ. Lund, Sweden, 2004).
45. Crichton, M. Next 418-419 (Harper Collins, 2008).
46. Huys, I. et al. Nat. Biotechnol. 27, 903-909 (2009).